Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
See this aricle in Pubmed

Article Abstract
Subcutaneous daclizumab HYP administered every 4 weeks led to clinically important effects on multiple sclerosis disease activity during 1 year of treatment. Our findings support the potential for daclizumab HYP to offer an additional treatment option for relapsing-remitting disease.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
complications
daclizumab
efficacy
immunotherapy
monoclonal antibodies
MRI
MRI,abnormal
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
safety
tumor necrosis factor inhibitor

Click Here to return To Results